Product image of Modiwart (Imiquimod) supplied by GNH India

Modiwart

Active Ingredient:
Imiquimod
Origin:
EU

Modiwart (Imiquimod)

Imiquimod, the active ingredient in Modiwart, is an immune response modifier presented as a topical formulation for cutaneous use. It is applied to the skin to treat precancerous lesions and certain viral skin conditions in adult patients.

GNH India supplies Modiwart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU quality standards and provides regulatory‑compliant shipments to global markets.

Manufacturer / TM Owner

Iasis Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imiquimod is used in dermatology to target abnormal skin growths and viral lesions.

  • Actinic keratosis: reduces and eliminates precancerous skin lesions.
  • Superficial basal cell carcinoma: promotes clearance of early‑stage skin cancer.
  • External genital warts: induces immune‑mediated regression of HPV‑related warts.

How It Works

  • Imiquimod acts as an agonist of Toll‑like receptor 7 (TLR7) on dendritic cells and keratinocytes. Activation of TLR7 triggers a signaling cascade that increases production of interferon‑α, tumor necrosis factor‑α, interleukins and other cytokines, enhancing local antiviral and antitumor immune responses. The resulting cellular immunity leads to apoptosis of dysplastic cells and clearance of viral infection.

Side Effects

Topical imiquimod may cause local and systemic reactions, most of which are mild to moderate.

Common Side Effects

  • Redness: localized erythema at the application site.
  • Itching: mild to moderate pruritus.
  • Burning sensation: transient heat feeling.
  • Swelling: edema of the treated area.
  • Crusting or scaling: formation of dry scabs.
  • Pain: discomfort or tenderness at the site.

Serious or Rare Side Effects

  • Severe allergic reaction: signs of anaphylaxis such as difficulty breathing or facial swelling.
  • Extensive skin ulceration: deep necrosis or persistent ulceration beyond the treated area.
  • Systemic flu‑like symptoms: fever, chills, headache or malaise.
  • Pigmentary changes: persistent hypopigmentation or hyperpigmentation of the skin.

Precautions & Warnings

When using Modiwart, follow prescriber guidance and observe safety measures.

  • Application frequency: follow prescriber instructions, typically once daily or as directed.
  • Treatment area: limit use to prescribed lesions; avoid healthy skin.
  • Sun exposure: protect treated skin from UV radiation to reduce irritation.
  • Pregnancy and lactation: use only if potential benefit justifies risk; consult healthcare provider.
  • Concomitant skin products: avoid using other topical medications or cosmetics on the same area unless approved.
  • Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Imiquimod may interact with other agents that affect immune function or skin integrity.

Major Interactions (Avoid)

  • Systemic immunosuppressants: may diminish imiquimod’s efficacy.
  • Live vaccines: increased risk of infection due to immune modulation.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids: can reduce local immune response and affect treatment outcome.
  • Antiviral agents applied to same site: potential for altered absorption.
  • Phototherapy: may increase skin irritation when combined.
  • Herbal skin preparations: possible additive irritation.

Frequently Asked Questions

Modiwart, containing imiquimod, is prescribed for the topical treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts. These conditions involve abnormal skin cell growth or human papillomavirus infection, and the medication works by stimulating a local immune response to clear the lesions.

Imiquimod functions as an agonist of Toll‑like receptor 7 (TLR7) on immune cells in the skin. By activating TLR7, it triggers the release of cytokines such as interferon‑α and interleukins, which enhance antiviral and antitumor activity. This immune activation leads to the destruction of dysplastic or virus‑infected cells.

The dosing regimen for Modiwart is determined by the prescribing clinician based on the specific indication, lesion size, and patient factors. The prescriber will provide detailed instructions on how much cream to apply, the frequency of application, and the total duration of therapy.

Safety data for imiquimod in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Modiwart, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with alternatives such as podophyllotoxin or sinecatechins, imiquimod (Modiwart) acts by stimulating the immune system rather than directly destroying viral tissue. This mechanism can result in longer treatment courses but may provide a broader antiviral effect and lower recurrence rates for certain patients.

Store Modiwart at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

Modiwart is applied topically to the affected skin area as directed by the prescriber. Typically, a thin layer is spread over the lesion, gently massaged in, and left on the skin for the prescribed period before washing off, unless the label specifies a different regimen.

Serious risks include severe allergic reactions such as anaphylaxis, extensive skin ulceration or necrosis, and systemic flu‑like symptoms. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face, deep ulceration, or high fever.

Modiwart should not be used by individuals with known hypersensitivity to imiquimod or any excipients in the formulation. It is also contraindicated in patients with active severe skin infections at the application site, or in those for whom the prescriber determines that the risks outweigh the benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Imiquimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT